Validated using a knockout cell line
Recombinant
RabMAb

Anti-IKK gamma antibody [EPR14660] (ab188569)

Overview

  • Product name
    Anti-IKK gamma antibody [EPR14660]
    See all IKK gamma primary antibodies
  • Description
    Rabbit monoclonal [EPR14660] to IKK gamma
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment within Human IKK gamma aa 150-300. The exact sequence is proprietary.
    Database link: Q9Y6K9

  • Positive control
    • HeLa, Jurkat, K572 and human fetal brain lysates. Jurkat cells.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab188569 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/10000 - 1/50000. Predicted molecular weight: 48 kDa.
ICC/IF 1/100.

Target

  • Function
    Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Also considered to be a mediator for TAX activation of NF-kappa-B. Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity (By similarity). Essential for viral activation of IRF3.
  • Tissue specificity
    Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.
  • Involvement in disease
    Defects in IKBKG are the cause of ectodermal dysplasia anhidrotic with immunodeficiency X-linked (EDAID) [MIM:300291]; also known as hypohidrotic ectodermal dysplasia with immunodeficiency (HED-ID). Is a form of ectoderma dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Characterized by absence of sweat glands, sparse scalp hair, rare conical teeth and immunological abnormalities resulting in severe infectious diseases.
    Defects in IKBKG are the cause of ectodermal dysplasia anhidrotic with immunodeficiency-osteopetrosis-lymphedema (OLEDAID) [MIM:300301].
    Defects in IKBKG are a cause of immunodeficiency NEMO-related without anhidrotic ectodermal dysplasia (NEMOID) [MIM:300584]; also called immunodeficiency without anhidrotic ectodermal dysplasia, isolated immunodeficiency or pure immunodeficiency. Patients manifest immunodeficiency not associated with other abnormalities, and resulting in increased infection susceptibility. Patients suffer from multiple episodes of infectious diseases.
    Defects in IKBKG are the cause of susceptibility to X-linked familial atypical micobacteriosis type 1 (AMCBX1) [MIM:300636]; also known as X-linked disseminated atypical mycobacterial infection type 1 or X-linked susceptibility to mycobacterial disease type 1. AMCBX1 is the X-linked recessive form of mendelian susceptibility to mycobacterial disease (MSMD). MSMD is a congenital syndrome resulting in predisposition to clinical disease caused by weakly virulent mycobacterial species, such as bacillus Calmette-Guerin vaccines and non-tuberculous, environmental mycobacteria. Patients are also susceptible to the more virulent species Mycobacterium tuberculosis.
    Defects in IKBKG are the cause of recurrent isolated invasive pneumococcal disease type 2 (IPD2) [MIM:300640]. Recurrent invasive pneumococcal disease (IPD) is defined as two episodes of IPD occurring at least 1 month apart, whether caused by the same or different serotypes or strains. Recurrent IPD occurs in at least 2% of patients in most series, making IPD the most important known risk factor for subsequent IPD.
    Defects in IKBKG are the cause of incontinentia pigmenti (IP) [MIM:308300]; formerly designed familial incontinentia pigmenti type II (IP2). IP is a genodermatosis usually prenatally lethal in males. In affected females, it causes abnormalities of the skin, hair, eyes, nails, teeth, skeleton, heart, and central nervous system. The prominent skin signs occur in four classic cutaneous stages: perinatal inflammatory vesicles, verrucous patches, a distinctive pattern of hyperpigmentation and dermal scarring.
  • Sequence similarities
    Contains 1 C2HC-type zinc finger.
  • Domain
    The leucine-zipper domain and the C2HC-type zinc-finger are essential for polyubiquitin binding and for the activation of IRF3.
  • Post-translational
    modifications
    Phosphorylation at Ser-68 attenuates aminoterminal homodimerization.
    Polyubiquitinated on Lys-285 through 'Lys-63'; the ubiquitination is mediated by NOD2 and RIPK2 and probably plays a role in signaling by facilitating interactions with ubiquitin domain-containing proteins and activates the NF-kappa-B pathway. Polyubiquitinated on Lys-399 through 'Lys-63'; the ubiquitination is mediated by BCL10, MALT1 and TRAF6 and probably plays a role in signaling by facilitating interactions with ubiquitin domain-containing proteins and activates the NF-kappa-B pathway. Monoubiquitinated on Lys-277 and Lys-309; promotes nuclear export. Linear polyubiquitinated on Lys-285; the head-to-tail polyubiquitination is mediated by the LUBAC complex. Linear polyubiquitinated on Lys-309; the head-to-tail polyubiquitination is mediated by the LUBAC complex.
    Sumoylated on Lys-277 and Lys-309 by SUMO1; the modification results in phosphorylation of Ser-85 by ATM leading to a replacement of the sumoylation by mono-ubiquitination on these residues.
  • Cellular localization
    Cytoplasm. Nucleus. Sumoylated NEMO accumulates in the nucleus in response to genotoxic stress.
  • Information by UniProt
  • Database links
  • Alternative names
    • IkB kinase associated protein 1 antibody
    • IkB kinase subunit gamma antibody
    • Inhibitor of nuclear factor kappa B kinase subunit gamma antibody
    • AMCBX1 antibody
    • FIP 3 antibody
    • FIP-3 antibody
    • FIP3 antibody
    • Fip3p antibody
    • I kappa B kinase gamma antibody
    • I-kappa-B kinase subunit gamma antibody
    • IkB kinase gamma subunit antibody
    • IkB kinase subunit gamma antibody
    • IkB kinase-associated protein 1 antibody
    • Ikbkg antibody
    • IKK-gamma antibody
    • IKKAP1 antibody
    • IKKG antibody
    • IMD33 antibody
    • Incontinentia pigmenti antibody
    • Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase gamma antibody
    • Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase of, gamma antibody
    • Inhibitor of nuclear factor kappa-B kinase subunit gamma antibody
    • IP antibody
    • IP1 antibody
    • IP2 antibody
    • IPD2 antibody
    • NEMO antibody
    • NEMO_HUMAN antibody
    • NF kappa B essential modifier antibody
    • NF kappa B essential modulator antibody
    • NF-kappa-B essential modifier antibody
    • NF-kappa-B essential modulator antibody
    • ZC2HC9 antibody
    see all

Images

  • Lane 1: Wild-type HAP1 cell lysate (20 µg)
    Lane 2: IKK gamma knockout HAP1 cell lysate (20 µg)
    Lane 3: Jurkat cell lysate (20 µg)
    Lane 4: K562 cell lysate (20 µg)
    Lanes 1 - 4: Merged signal (red and green). Green - ab188569 observed at 50 kDa. Red - loading control, ab8245, observed at 37 kDa.

    ab188569 was shown to react with IKK gamma in wild-type HAP1 cells along with additional cross-reactive bands. No band was observed when IKK gamma knockout samples were examined. Wild-type and IKK gamma knockout samples were subjected to SDS-PAGE. ab188569 and ab8245 (loading control to GAPDH) were diluted 1/10,000 and 1/1000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776 secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.

  • All lanes : Anti-IKK gamma antibody [EPR14660] (ab188569) at 1/10000 dilution

    Lane 1 : Hela cell lysate
    Lane 2 : Jurkat cell lysate
    Lane 3 : K562 cell lysate
    Lane 4 : Human fetal brain lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

    Predicted band size: 48 kDa
    Additional bands at: 41 kDa (possible cleavage fragment)

  • Immunocytochemical analysis of Jurkat cells fixed in 4% paraformaldehyde labeling IKK gamma with ab188569 at 1/100 dilution and Goat anti rabbit IgG(Alexa Fluor® 555) at 1/200 dilution.  Counterstained with DAPI.

References

ab188569 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab188569.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up